Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Rhu-Epo down-regulates pro-tumorigenic activity of cancer-associated fibroblasts in multiple myeloma

Rhu-Epo down-regulates pro-tumorigenic activity of cancer-associated fibroblasts in multiple myeloma We have previously demonstrated that recombinant human erythropoietin (rHuEpo) is involved in the regulation of the angiogenic response in multiple myeloma (MM) through a direct effect on macrophages and endothelial cells isolated from the bone marrow of patients with MM. The aim of the present study was designed to determine the effects of rHuEpo on cancer-associated fibroblasts (CAFs) from monoclonal gammopathy of undetermined significance (MGUS) and MM patients by means of in vitro and in vivo assays. rHuEpo treatment reduces the expression of mRNA levels of fibroblast activation markers, namely alpha smooth actin (αSMA) and fibroblast activation protein (FAP) in MGUS and MM CAFs, and of pro-inflammatory and pro-angiogenic cytokines, including interleukin (IL)-6 and IL-8, vascular endothelial growth factor-A (VEGF-A), fibroblast growth factor-2 (FGF-2), and hepatocyte growth factor (HGF) in MM CAFs. Moreover, rHuEpo inhibits the proliferative activity of MM CAFs and increased the apoptosis of MGUS and MM CAFs. Overall, these data suggest that rHu-Epo down-regulates CAFs pro-tumorigenic activity. Moreover, these results are not suggestive for a pro-angiogenic activity of rHuEpo on CAFs. In fact, rHuEpo pre-treatment induces a low angiogenic response in vivo in the chorioallantoic membrane (CAM) assay of MGUS and MM CAFs conditioned medium, not comparable to that of a well-known angiogenic cytokine, VEGF-A, tested in the same assay. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of Hematology Springer Journals

Rhu-Epo down-regulates pro-tumorigenic activity of cancer-associated fibroblasts in multiple myeloma

Download PDF
8 pages

Loading next page...
 
/lp/springer_journal/rhu-epo-down-regulates-pro-tumorigenic-activity-of-cancer-associated-OXiYPPkhu8
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer-Verlag GmbH Germany, part of Springer Nature
Subject
Medicine & Public Health; Hematology; Oncology
ISSN
0939-5555
eISSN
1432-0584
DOI
10.1007/s00277-018-3293-x
pmid
29589107
Publisher site
See Article on Publisher Site

Abstract

We have previously demonstrated that recombinant human erythropoietin (rHuEpo) is involved in the regulation of the angiogenic response in multiple myeloma (MM) through a direct effect on macrophages and endothelial cells isolated from the bone marrow of patients with MM. The aim of the present study was designed to determine the effects of rHuEpo on cancer-associated fibroblasts (CAFs) from monoclonal gammopathy of undetermined significance (MGUS) and MM patients by means of in vitro and in vivo assays. rHuEpo treatment reduces the expression of mRNA levels of fibroblast activation markers, namely alpha smooth actin (αSMA) and fibroblast activation protein (FAP) in MGUS and MM CAFs, and of pro-inflammatory and pro-angiogenic cytokines, including interleukin (IL)-6 and IL-8, vascular endothelial growth factor-A (VEGF-A), fibroblast growth factor-2 (FGF-2), and hepatocyte growth factor (HGF) in MM CAFs. Moreover, rHuEpo inhibits the proliferative activity of MM CAFs and increased the apoptosis of MGUS and MM CAFs. Overall, these data suggest that rHu-Epo down-regulates CAFs pro-tumorigenic activity. Moreover, these results are not suggestive for a pro-angiogenic activity of rHuEpo on CAFs. In fact, rHuEpo pre-treatment induces a low angiogenic response in vivo in the chorioallantoic membrane (CAM) assay of MGUS and MM CAFs conditioned medium, not comparable to that of a well-known angiogenic cytokine, VEGF-A, tested in the same assay.

Journal

Annals of Hematology – Springer Journals

Published: Mar 28, 2018

References

  • Bone marrow angiogenesis and progression in multiple myeloma
    Vacca, A; Ribatti, D; Roncali, L; Ranieri, G; Serio, G; Silvestris, F; Dammacco, F
  • Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma
    Ribatti, D; Nico, B; Vacca, A
  • Bone marrow fibroblasts parallel multiple myeloma progression in patients and mice: in vitro and in vivo studies
    Frassanito, MA; Rao, L; Moschetta, M; Ria, R; Marzo, L; Luisi, A; Racanelli, V; Catacchio, I; Berardi, S; Basile, A
  • Mast cells contribute to vasculogenic mimicry in multiple myeloma
    Nico, B; Mangieri, D; Crivellato, E; Vacca, A; Ribatti, D
  • Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma
    Ribatti, D; Vacca, A; Nico, B; Quondamatteo, F; Ria, R; Minischetti, M; Marzullo, A; Herken, R; Roncali, L
  • Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma
    Scavelli, C; Nico, B; Cirulli, T; Ria, R; Pietro, G; Mangieri, D; Bacigalupo, A; Mangialardi, G; Coluccia, AML; Caravita, T
  • Endothelial cells in the bone marrow of patients with multiple myeloma
    Vacca, A; Ria, R; Semeraro, F; Merchionne, F; Coluccia, M; Boccarelli, A; Scavelli, C; Nico, B; Gernone, A; Battelli, F
  • Nonclassic endogenous novel regulators of angiogenesis
    Ribatti, D; Conconi, MT; Nussdorfer, GG
  • Angiogenic effects of erythropoietin
    Ribatti, D
  • Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo
    Ribatti, D; Presta, M; Vacca, A; Ria, R; Giuliani, R; Dell'Era, P; Nico, B; Roncali, L; Dammacco, F
  • Erythropoietin is involved in the angiogenic potential of bone marrow macrophages in multiple myeloma
    Luisi, A; Binetti, L; Ria, R; Ruggieri, S; Berardi, S; Catacchio, I; Racanelli, V; Pavone, V; Rossini, B; Vacca, A
  • Role of erythropoietin in the angiogenic activity of bone marrow endothelial cells of MGUS and multiple myeloma patients
    Lamanuzzi, A; Saltarella, I; Ferrucci, A; Ria, R; Ruggieri, S; Racanelli, V; Rao, L; Annese, T; Nico, B; Vacca, A; Ribatti, D
  • Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method
    Livak, KJ; Schmittgen, TD
  • The gelatin sponge–chorioallantoic membrane assay
    Ribatti, D; Nico, B; Vacca, A; Presta, M
  • The local HIF-2α/EPO pathway in the bone marrow is associated with excessive erythrocytosis and the increase in bone marrow microvessel density in chronic mountain sickness
    Su, J; Li, Z; Cui, S; Ji, L; Geng, H; Chai, K; Ma, X; Bai, Z; Yang, Y; Wuren, T; Ge, RL; Rondina, MT
  • Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion
    Orimo, A; Gupta, PB; Sgroi, DC; Arenzana-Seisdedos, F; Delaunay, T; Naeem, R; Carey, VJ; Richardson, AL; Weinberg, RA
  • Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-κB-dependent manner
    Erez, N; Truitt, M; Olson, P; Hanahan, D
  • Erythropoietin decreases the occurrence of myocardial fibrosis by inhibiting the NADPH-ERK-N-kB pathway
    Wang, L-P; Yang, X-H; Wang, X-J; Li, S-M; Sun, N; Zhang, T
  • The myocardium protective effects of erythropoietin (EPO) in a rat model of asphyxia-induced cardiac arrest/cardiopulmonary resuscitation (CPR)
    Jiang, HL; Zhu, YC; Chen, XH; Lin, PY; Wang, HJ
  • Reduction of inflammatory cytokine expression and oxidative damage by erythropoietin in chronic heart failure
    Li, Y; Takemura, G; Okada, H; Miyata, S; Maruyama, R; Li, L; Higuchi, M; Minatoguchi, S; Fujiwara, T; Fujiwara, H
  • Erythropoietin ameliorates renal interstitial fibrosis via the inhibition of fibrocyte accumulation
    Geng, XC; Hu, ZP; Lian, GY